Skip to Main Content

NEWS & RESOURCES

Bioscience

Positive Session for Bioscience Sector

The 2026 General Assembly session was one of the least contentious in recent memory for the biopharma sector. Bills calling for innovation-sapping price controls and unworkable programs…

Boehringer Partners on Connecticut Science Center STEM Lab

The Connecticut Science Center is home to exhibits, programs, and…

Costly Public Option Precursor Advances

The Connecticut General Assembly is exploring ways to address rising…

Content Type:

Bioscience

ViiV Healthcare team

ViiV Healthcare’s HIV, AIDS Efforts Recognized

Branford pharmaceutical company ViiV Healthcare is being recognized for...

Bioscience

Amended Healthcare Regulatory Bill Heads to House

The state Senate passed omnibus legislation imposing a broad...

Bioscience

Trump’s Misguided Attempt to Lower Drug Prices

President Trump’s executive order linking what the U.S. government...

Bioscience

MADE Leadership Series Connects with Yale Innovation Summit

The second in the new MADE business leadership series...

Bioscience

For Safety’s Sake, Sales Reps Need Privacy

The outcome of the three most consequential biopharma bills...

Bioscience

‘Self-Inflicted Wound:’ Tax Hikes, Weaker Guardrails Mark Budget Plan

The state legislature’s tax and spending committees this week...

Bioscience

Time to Undo the Pill Penalty

Ever wonder why so many of the drug commercials...

Bioscience

How to Reduce Prescription Drug Costs

Three prescription drug bills remain in play in the...

Bioscience

Lower Drug, Healthcare Costs? Bills Miss the Mark.

If the definition of insanity is doing the same...

Stay Connected with CBIA News Digests

The latest news and information delivered directly to your inbox.